OSOD has conducted over 1000 projects in our 30-year history spanning the development process from initial iterative investigative studies, to chronic GLP-compliant safety studies, to advising on clinical testing strategy.
The eye is often at the forefront of innovatative therapies and we have been involved with many. Our skilled ophthalmologists and technicans have the ability to administer therapies and evaluate their safety in all laboratory animal species from rodents, to minipigs, to nonhuman primates.
As a primary preclinical partner for the development of approved ophthalmic therapies and clinical testing approval for many others, we know our approach works.
O'Neill, C.A., et.al., 2003. 26-week intravitreal injection toxicity study with rhuFab VEGF in cynomolgus monkeys with an 8-week recovery. Investigative Ophthalmology & Visual Science, 44(13).Eylea - 2011
Zimmer, E., et.al., 2006. Safety evaluation of intravitreal administration of VEGF trap in cynomolgus monkeys for 13 weeks. Investigative Ophthalmology & Visual Science, 47(13).Xiidra - 2016
Murphy, C. J., et.al., 2011. The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs. Investigative ophthalmology & visual science, 52(6).Susvimo - 2020
Bantseev, V., et.al., 2020. Evaluation of surgical factors affecting vitreous hemorrhage following port delivery system with ranibizumab implant insertion in a minipig model. Retina (Philadelphia, Pa.), 40(8).Durysta - 2021
Shen, J., et.al., 2020. Nonclinical pharmacokinetic and pharmacodynamic assessment of bimatoprost following a single intracameral injection of sustained-release implants. Translational Vision Science & Technology, 9(4).